Nanotechnology Now - Press Release: Food and Drug Law Institute, Project on Emerging Nanotechnologies Co-Sponsor Major Conference on Nanotechnology Law, Regulation and Policy

Home > Press > Food and Drug Law Institute, Project on Emerging Nanotechnologies Co-Sponsor Major Conference on Nanotechnology Law, Regulation and Policy

Abstract:
Top Government Officials Will Explain Regulatory Plans for Cutting-Edge Technology at National Meeting Feb. 28-29 in Washington, DC.

Food and Drug Law Institute, Project on Emerging Nanotechnologies Co-Sponsor Major Conference on Nanotechnology Law, Regulation and Policy

Washington, DC | Posted on December 6th, 2007

Nanotechnology was incorporated into more than $50 billion in manufactured goods last year, according to Lux Research. By 2014, the market will grow to $2.6 trillion. By 2011, over $15 billion in nano-enabled drugs and therapeutics will be sold -- up from more than $3 billion in 2006. And industry experts project that nanotechnology will be incorporated into $20 billion worth of consumer
food products by 2010.

Yet, despite this rapid commercialization, no nano-specific regulation
exists anywhere in the world. Most regulatory agencies remain in an
information-gathering mode -- lacking the legal and scientific tools,
information and resources they need to adequately oversee exponential
nanotechnology market growth.

Now, for the first time, top officials at the agencies responsible for
the regulation of nanotechnology products -- including the Food and Drug
Administration, Environmental Protection Agency, Occupational Safety and
Health Administration and Department of Agriculture -- will meet at a Food
and Drug Law Institute conference to discuss their plans for managing and
monitoring these products.

At FDLI's 1st Annual Conference on Nanotechnology Law, Regulation and
Policy, February 28-29, 2008, at the L'Enfant Plaza Hotel, in Washington,
D.C., food and drug industry representatives also will find out what's
happening internationally on nanotech regulation, how venture capitalists
look at the future of nanotechnology and what the leading corporations,
scientific laboratories and academic centers are focusing on in this
dynamic field.

This groundbreaking conference, co-sponsored by the Woodrow Wilson
International Center for Scholars' Project on Emerging Nanotechnologies, in
partnership with Arizona State University and the Burdock Group, will
address the crucial issues surrounding nanotechnology law, regulation and
policy, including:

-- What first and second generation nanotechnology products already are
on the market, and what is to come?

-- Is Congress ready to act on nanotechnology if federal regulators do
not?

-- Do Europe and Asia approach nanotechnology safety and oversight
differently than the United States?

-- How do consumers see nanoproducts?

-- When it comes to nanotechnology, should size make a regulatory
difference?

Michael Taylor, Research Professor of Health Policy, School of Public
Health and Health Services, The George Washington University, and author of
the most comprehensive report published on nanotechnology regulation at
FDA, Regulating the Products of Nanotechnology, Does FDA Have the Tools It
Needs?, will present the keynote address. Also, Sen. Ron Wyden (D-Ore.),
co-chair of the Congressional Nanotechnology Caucus, and invited luncheon
speaker, will discuss future congressional actions in this area.

Top-level FDA officials, including Associate Commissioner for Science
Norris Alderson; Deputy Commissioner for Policy Randall W. Lutter; Deputy
Associate General Counsel Jeffrey Senger; and Director of Food Additive
Safety Laura Tarantino, will appear on a special panel on FDA regulation of
nanotechnology.

Other featured speakers and moderators include:

Jay M. Ansell, Personal Care Products Council;

Susan D. Brienza, Of Counsel, Patton Boggs LLP;

George Burdock, President, Burdock Group;

Robert W. Carpick; University of Pennsylvania Director, The
Nanotechnology Institute;

Ricardo Carvajal; Counsel, Reed Smith LLP;

Jim Czaban, Partner, WilmerHale;

Lee Farrow, Senior Vice President, ACE Medical Risk;

Piotr Grodzinski, Director, NCI Alliance for Nanotechnology in Cancer,
NIH;

Ralph Hall, Professor, University of Minnesota Law School;

Robert A. Hoerr, President & CEO, Nanocopoeia, Inc.;

Michael Holman. Senior Analyst, Lux Research;

Karen Hunter, Program Specialist, U.S. Department of Agriculture,
Cooperative State Research, Education and Extension Service;

Rachel G. Lattimore, Partner, Arent Fox LLP;

Scott Livingston, Managing Director, Axiom Capital Management/The
Livingston Group;

Jane Macoubrie, President, Embry Research;

Ellen Maldenado, Attorney-at-Law;

Gary Marchant, Lincoln Professor of Emerging Technologies, Law & Ethics

Sandra Day O'Connor College of Law;

Philippe Martin, Principal Administrator, Nanotechnologies Policy
Development and Coordination, Consumer Protection Directorate (DG-SANCO),
European Commission;

Terry L. Medley, Global Director, Corporate Regulatory Affairs, DuPont
Environment and Sustainable Growth Center;

Julia A. Moore, Deputy Director, Project on Emerging Nanotechnologies,
Woodrow Wilson International Center for Scholars;

Sean Murdock, Executive Director, NanoBusiness Alliance;

Fern P. O'Brian, Partner, Arnold & Porter LLP;

Leon Radomsky, Chair, Nanotechnology Industry Team, Foley & Lardner
LLP;

David W. Rejeski, Director, Project on Emerging Nanotechnologies,
Woodrow Wilson International Center for Scholars;

Stephanie Scharf, Partner, Schoeman Updike Kauffman & Scharf;

Dietram Scheufele, Professor of Life Sciences Communication, University
of Wisconsin;

Loretta Schuman, Occupational Safety and Health Administration;

Laura Sciarrino, Vice President, Legal, CV Therapeutics, Inc.; and

Jim Willis, U.S. Environmental Protection Agency.

The Project on Emerging Nanotechnologies is an initiative launched by
the Woodrow Wilson International Center for Scholars and The Pew Charitable
Trusts in 2005. It is dedicated to helping business, government and the
public anticipate and manage possible health and environmental implications
of nanotechnology.

Burdock Group has more than 20 years of expertise regarding ingredient
safety and regulatory consultation services. Burdock Group's team offers
mission-critical services that include Generally Recognized as Safe (GRAS),
New Dietary Ingredient Notifications (NDINs), Consumption Analysis, Claims
substantiation, Toxicology and Risk Assessment, Literature Searches and
Label Reviews. For more information, visit http://www.BurdockGroup.com.

The Center for the Study of Law, Science & Technology at Arizona State
University is the nation's oldest and largest academic center focusing on
the intersection of law with science and technology, and is currently
engaged in a three-year study funded by the DOE on regulation of
nanotechnology.

To register for the conference, visit http://www.fdli.org or call (800)
956-6923 or (202) 371-1420.

####

About Food & Drug Law Institute
Founded in 1949, FDLI publishes the award-winning, peer-reviewed Food
and Drug Law Journal; the bimonthly magazine Update; FDA Directory; and
dozens of books and publications for attorneys, regulatory affairs
practitioners, scientists, health care professionals, government employees
and marketers in the food and drug field.

For more information, please click here

Contacts:
Michael Levin-Epstein
Editor-in-Chief
FDLI
(202) 222-0897

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: